Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
To establish the efficacy and safety of a new tablet formulation and dosing regimen of
balsalazide disodium dosed twice daily in achieving clinical improvement in subjects with
mildly to moderately active ulcerative colitis after 6 weeks of therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.